Alimera Sciences announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE), in its Final Appraisal Determination for national reimbursement, has recommended funding for Iluvien 190 micrograms intravitreal implant in applicator for the prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment (NIPU).
“The NICE coverage decision for Iluvien is welcome news for patients in the U.K. suffering from this disease, as reducing relapse is a priority in the management of this condition,”Carlos Pavesio, Specialist Uveitis Consultant Ophthalmologist at Moorfields Eye Hospital, London, said in a company news release. “Preventing vision loss associated with relapse has a huge impact on patients’ quality of life.”
In the United Kingdom, a NICE recommendation for funding signifies that the country’s National Health Service (NHS) will pay for Iluvien prescriptions for the treatment of NIPU as part of its offering. Iluvien is also funded for the treatment of diabetic macular edema (DME) in the United Kingdom. More information on the recommendation can be found on the NICE website at https://www.nice.org.uk/news/article/innovative-treatment-for-inflammatory-eye-condition-recommended-for-use-on-the-nhs.
“The Birdshot Uveitis Society and our members are delighted that NICE has approved the Iluvien implant for use in posterior uveitis patients,” Annie Folkard, founding member of The Birdshot Uveitis Society, said in the news release. “It is a very welcome development as this slow-release steroid implant offers a very effective treatment directly targeting inflammation in the eye without a lot of the unpleasant side effects of more systemic drugs that have been frequently used in the past.”
“We continue to execute on our plans to launch Iluvien’s new indication in Europe for noninfectious posterior uveitis, a significant and, we believe, poorly-served medical need. The positive funding recommendation from NICE facilitates patient access in England and Wales for this second indication with funding from the NHS,” said Rick Eiswirth, president and CEO of Alimera Sciences. “Iluvien’s unique CONTINUOUS MICRODOSING technology provides important sustained benefits in patients diagnosed with both posterior uveitis and DME, and we are pleased to work with physicians and the National Health Service in the U.K. to expand its availability.”